Financial TimesMerck lung cancer trial boosts immunotherapy hopesFinancial TimesImmunotherapy is set to become the default treatment for the vast majority of lung cancer patients after a clinical trial from drugmaker Merck & Co showed that adding i… Continue reading
New York TimesLung Cancer Patients Live Longer With Immune TherapyNew York TimesThe findings should change medical practice immediately, cancer experts say: Patients with this type of lung cancer should receive an immune-activating drug, also called im… Continue reading
FierceBiotech |
Lysogene delays Sanfilippo gene therapy phase 3
FierceBiotech A manufacturing delay has pushed back the start of Lysogene’s pivotal Sanfilippo syndrome trial. The gene therapy study is now due to get underway in the second half of the year. Paris, France-based Lysogene wrapped up preclinical toxicology work on … Lysogene Reports First Quarter Financial Results and Provides Business UpdateMarkets Insider Gene Therapy Market | Industry Outlook Research Report Till 2024 By decisionDatabasesThe Mobile Herald Global PharmaSphere: Emerging Biotechnologies-Gene Therapy Market 2018 Review- AnGes MG, Advantagene and …Investor Opinion The Chronicle of News –satPRnews (press release) all 6 news articles » |
Mass Device |
OncoSec looks to boost effects of immunotherapy with intratumoral delivery
Mass Device Thousands of cancer patients have been treated with immune checkpoint inhibitors since the first of its kind was approved in 2011. The product is designed to block the production of proteins that prevent the body’s immune system from acting in the … |
Benzinga |
Exclusive: Ziopharm Oncology CEO Wants To Disrupt The CAR–T Supply Chain
Benzinga Ziopharm Oncology Inc. (NASDAQ: ZIOP) has two goals. One is to disrupt the narrative around recurrent glioblastomas. The other is to disrupt the entire pharmaceutical supply chain. The latter pursuit isn’t just a B2B revenue opportunity, it’s meant to … |